Harry H. Penner, Jr., J.D., L.L.M.

Chairman and CEO, Nascent Bioscience, LLC

Mr. Penner became a director of Celldex in January 1997. He is Founder, Chairman and Chief Executive Officer of Nascent BioScience, LLC, a firm engaged in the creation and development of new biotechnology companies founded in September 2001. Mr. Penner is a Founder of New Haven Pharmaceuticals (of which he is Chairman and Chief Executive Officer), Prevention Pharmaceuticals, Affinimark Technologies, Rib-X Pharmaceuticals, RxGen, MAK Scientific, and Marinus Pharmaceuticals. He was President, Chief Executive Officer, and Vice Chairman of Neurogen Corporation from 1993 to 2001. From 1985 to 1993 he was an Executive Vice President of Novo Nordisk A/S, serving from 1988 to 1993 as Executive Vice President for North America and President, Novo Nordisk of North America, and from 1985 to 1988 as the company's Executive Vice President and General Counsel in Denmark. He has served as BioScience Advisor to the Governor and the State of Connecticut, as Co-Chair of Connecticut United for Research Excellence, and as Chair of the Connecticut Board of Governors of Higher Education. He currently serves on the Boards Rib-X, New Haven Pharmaceuticals, Prevention Pharmaceuticals, and Affinimark. Mr. Penner holds a B.A. from the University of Virginia, a J.D. from Fordham University, and an L.L.M. in International Law from New York University.